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Behcet’s disease is a multisystem disease characterized by recurrent oral and genital ulcers, relapsing uveitis, mucocutaneous,
articular, gastrointestinal, neurologic, and vascular manifestations. Rheumatologic manifestations may also occur in Behcet’s
disease, and arthritis and arthralgia are the most common musculoskeletal ﬁndings followed by enthesopathy, avascular necrosis,
myalgia,andmyositis.AlthoughthemainpathologyofBehcet’sdiseasehasbeenknowntobetheunderlyingvasculitis,theetiology
and exact pathogenesis of the disease are still unclear. Musculoskeletal ﬁndings of Behcet’s disease, the relationship between
Behcet’s disease and spondyloarthropathy disease complex, and the status of bone metabolism in patients with Behcet’s disease
were discussed in this paper.
1.Introduction
Behcet’s disease (BD) is a chronic and recurrent multisys-
temic disorder, mainly characterized by oral and genital aph-
thous ulcers, skin lesions, and uveitis, occasionally resulting
from inﬂammation in central nervous and gastrointestinal
system, lungs, kidneys, and joints [1]. Additionally, BD is
described as a systemic, vasculitic disorder in which both
arteries and veins of any kind of organ may involve [2].
The disease may be distributed worldwide, but it is more
prevalent in Asian and Mediterranean regions [3].
TheetiologyandpathogenesisofBDstillremainobscure.
However, both genetic and environmental factors, such
as microbial pathogens, have been proposed to initiate a
congenital and/or acquired immune dysfunction that cause
development of the clinical manifestations of the disease
[4]. Musculoskeletal involvement in BD is one of the most
frequent ﬁndings among the clinical manifestations. Table 1
summarizes the musculoskeletal ﬁndings of BD, found in the
medical literature. Arthritis and arthralgia are the most com-
mon musculoskeletal ﬁndings of the disease [5]. Although
the frequency of the arthritis has been increasing, it has not
been yet included in any International Study Group (ISG)
Criteria of BD [6]. Furthermore, it was also claimed that
the disease could be classiﬁed into the spondyloarthropathy
(SpA) complex, because of the presence of sacroiliitis in BD
and the clinical overlap between BD and some disease of
the SpA complex [7]. On the other hand, the chronicity
and factors involved in inﬂammatory process of the disease
and the drugs used for the treatment of BD might have
negative eﬀects on bone remodeling, consequently resulting
in osteoporosis in BD [8].
In this paper, musculoskeletal ﬁndings of BD, the re-
lationship between BD and SpA disease complex, and oste-
oporosis were discussed.
2. Arthritis
Arthritisandarthralgiaarethemostcommonrheumatologic
ﬁndings in BD and their prevalence varies between 40 and
70% [1, 5, 9]. Subjects with arthritis in BD predominantly
present with recurrent, self-limited, nondeforming and
nonerosive, inﬂammatory asymmetric mono-oligoarthritis,
aﬀecting most frequently the larger joints suck, as knees,
wrists, ankles and elbows [1, 5, 6, 9, 10]. Erosive forms of
arthritis in BD have been reported in only small number
of cases, and the most eﬀected locations are axial joint
(sacroiliac), enthesis (calcaneal), and peripheral joints such
as metatarsophalangeal and interphalangeal joints of the feet2 Pathology Research International
Table 1: Rheumatologic ﬁndings reported in medical literature.
Findings Localization Percentage (%)
Joint Involvement Arthritis/Arthralgia 40–70 [9, 14]
K n e e ,w r i s t ,a n k l e ,e l b o w ,h a n d ,f e e t 1 0 – 5 6[ 9, 13]
Sacroiliac 0–63 [15, 16]
Manubrio-sternal, sterno-clavicular Unknown [17]
Enthesopathy Calcaneal and vertebral bone spurs 3–36 [7, 18]
Bone Mineral Density Vertebral osteoporosis Unknown [19]
Muscle Involvement Myalgia or myositis Unknown [10, 20]
Fibromyalgia 9.3 [21]
Bone Infarct Osteonecrosis Unknown [22]
and intercarpal and metacarpophalangeal joints of the hand,
wristandknee[11,12].ClinicalhandinvolvementinBDwas
investigated extensively in a study where the prevalence of
hand involvement in the disease was found to be high [13].
They also found that the terminal phalangeal tuft resorption
that might be related to a speciﬁc pattern, induced by the
vasculitic process due to the repeated digital infarcts, and the
rheumatoid-like handﬁndings werethe most frequenthands
in patients with BD.
The mechanism of arthritis is not fully understood,
but inﬂammation and hyperemia (synovitis) are tried to
be explained by vasculitis that constitutes the primary pa-
thology in BD [23]. Synovial inﬂammation has been dem-
onstrated in various reports where hypertrophy and hyper-
plasia of synovial lining cells, hypervascularity, subsyn-
ovial accumulation of inﬂammatory cells, and replacement
of superﬁcial zones of the synovial membrane by dense
inﬂamed granulation tissue were described, without involve-
ment of the deeper layers [5, 9, 24]. However, Moll et al.
suggested that synovitis was characterized by large areas of
hyperemic synovitis without villi or a distinctive vascular
p a t t e r ni ne a r l yu n t r e a t e dB D[ 25]. Ca˜ nete et al. stated
that the polymorphonuclear neutrophil and lymphocytes, as
important inﬁltrating cell populations, were found to be the
indicators of cytotoxic molecules in early untreated synovitis
in BD [26]. The authors also claimed that no evidence
for neutrophilic vasculitis and no any other form of vessel
pathology in the synovial pathology were detected.
Although there is no clear consensus on its etiology in
terms of autoimmunity, some authors have declared that
BD could be considered as an autoinﬂammatory disease
due to the fact that both diseases may have the similar
clinical characteristics [27]. However, investigations showed
noevidenceofincreaseinantibodyconcentrationandT-cell-
speciﬁc antigens in BD [28, 29].
BD is mostly diagnosed according to ISG Criteria for
BD [30]. Although arthritis is seen in more than half of
the subjects, it has not been considered among the ISG
Criteria for BD. A possible explanation for this exception
is that complaints about joints in society are very com-
mon, and, therefore, investigators ignore to consider these
complaints or ﬁndings among the symptoms of the disease
[6]. Since the laboratory ﬁndings in BD are nonspeciﬁc,
its diagnosis is based exclusively on clinical evaluation of
subjects. A detailed clinical history and classic manifestation
of nonerosive arthritis on physical examination is diagnostic
for BD. However, the presence of destructive lesions may
confuse the diagnosis of BD and lead to investigate for
another cause of destructive lesions, such as rheumatoid
arthritis, psoriatic arthritis, and ankylosing spondylitis (AS)
[23]. In vast majority of the patients with BD, colchicine
(1-2mg/day) is the drug of choice for the management of
nonerosivearthritis[5].However,destructivearthritiscovers
a broad spectrum of therapeutic alternatives, including
colchicineandnonsteroidalanti-inﬂammatorydrugsatﬁrst-
line treatment, local corticosteroid injections, and low-dose
systemic corticosteroids [10, 23]. Azathioprine and tumor
necrosis factor-alpha (TNF-α) blockers may have some
beneﬁcial eﬀects in rare cases with resistant, longer-lasting,
and disabling conditions [31].
3.Spondyloarthropathy andBehcet’s Disease
Oneoftheremarkablequestionsinthepastwastheinclusion
of BD in SpA disease complex. Since some investigators
have reported the high prevalence of sacroiliitis associated
to BD, the coexistence of BD and AS, and the presence of
clinical overlap between BD and some subgroup of SpA
disease complex such as inﬂammatory bowel disease and
Reiter’s syndrome, they claimed that BD could be included
in seronegative SpA group [7, 32, 33]. The issue of sacroiliitis
associatedwithBDhadbeenexclusivelyinvestigated,andthe
prevalence of sacroiliitis in BD was highly variable. Yazici
et al. have stated that high prevalence of sacroiliitis, found
in studies, may be due to the fact that most of the studies
had no control groups. Moreover, they claimed that intra-
and interobserver variability in interpreting the AP pelvis
radiographs is high [34]. Some authors have found that the
prevalence of sacroiliitis has not been diﬀe r e n tf r o mt h a ti n
general population [15, 34].
The diseases in SpA group have some similar common
features. One of the most striking associations among the
clinical characteristics in SpA complex is with the enthesitis,
HLA-B27 antigen, eye involvement [7, 35]. Although there
have been conﬂicting results for the prevalence of HLA-B27
in patients with BD, BD seems to be associated with
HLA-B51 rather than HLA-B27 [7, 36]. There are also somePathology Research International 3
reports regarding the presence of acne-associated arthritis
in a subgroup of patients with BD that may be considered
within the broader concept of SpA disease complex [37].
Furthermore, Hatemi et al. have stated that the increased
presence of enthesopathy in BD who also have acne and ar-
thritis compared with that BD without arthritis supported
the hypothesis that the BD having also acne and arthritis
form a distinct cluster [35]. Findings of investigations
regarding the prevalence of enthesopathy in BD are incon-
sistent. The prevalence of enthesopathy has been found to
be higher (38%) in some clinical trials [9, 18], but lower
rates (3.4%) has also been reported [7]. This wide variation
in the reported frequency in BD was explained by the fact
thatradiographyandphysicalexaminationwerenotsensitive
methods for detecting enthesopathy and the diﬀerences in
selected study groups [35]. On the other hand, the pattern
of eye involvement is known to be diﬀerent between SpA and
BD. The uveitis of SpA mostly is in benign character, whereas
uveitis in BD occasionally results in loss of vision [38].
Conclusively, the lack of clear association of HLA-B27
and BD, the disparity of the eye involvement in SpA and
BD, and conﬂict reports on sacroiliitis and enthesitis in BD
have complicated the enrollment of the BD into SpA disease
complex.
4.Bone Metabolism
The chronicity and vasculitic background of the disease
and the drugs for the treatment of BD suggest that bone
metabolism might be aﬀected negatively, which then leads
to bone loss, resulting in osteoporosis in patients with BD
[8]. Osteoporosis is a common disease characterized by a
systemic impairment of bone mass and microarchitecture
that causes fragility fractures [39]. The pathogenesis of
osteoporosis is mainly considered as an imbalance of the
remodeling process, and inﬂammatory molecules, such as
proinﬂammatory cytokines, interleukins, and TNF-α play an
imported role to regulate bone metabolism [39, 40]. On the
other hand, the primer pathology in BD is inﬂammatory
process of small arteries and veins and thrombosis as a
result of vasculitis of vasa vasorum [41]. Elevated levels
of immunoglobulins, immune complexes, and complement
and acute-phase proteins reveal that the immune system
is also involved and activated in the disease process [42].
Investigations demonstrated that interleukins and TNF-α
levelhavebeenfoundtobehighinpatientswithBD[43,44].
Additionally, Hamzaoui et al. reported that vitamin D
insuﬃciency may modulate inﬂammatory mediators skew-
ing the Th1/Th2 balance towards Th1 [45]. However, it
is not known whether the chronic nature of the disease
and these activated inﬂammatory molecules aﬀect the bone
remodeling or turnover in patients with BD [5, 9, 14].
There are limited numbers of clinical trial that reveal the
status of bone metabolism and bone mineral density (BMD)
in the medical literature, and ﬁndings in these investigations
are in consistent [8, 19, 46]. First, the status of BMD was
investigated in a study, where BMD measurements of lumbar
spine and hip in BD showed similar results when compared
to those in healthy subjects [8]. Additionally, Tekin et al.
stated that there was no signiﬁcant relationship between
arthritis and BMD, and bone turnover markers in patients
with BD. The authors also declared that they found no
statisticallysigniﬁcantdiﬀerencesinBMDandboneturnover
markers between BD and control groups [46]. Recently,
conﬂicting with previous reports, Kirnap et al. have stated
that they found signiﬁcant diﬀerences in BMD values of
lumbar spine and serum bone speciﬁc alkaline phosphatase
between BD and healthy controls, indicating that BD can
be a risk factor for osteoporosis in lumbar vertebra [19].
Despite these eﬀorts, to what extent the BMD and bone
remodelinginpatientswithBDareinvolvedisstillunknown.
Further studies with larger study groups, especially relevant
to bone turnover aﬀecting the immunopathogenesis of
bone metabolism and BMD in patients with BD should be
considered.
In summary, the clinical characteristics of BD are the
recurrent episodes of remission and the exacerbations of
various symptoms including musculoskeletal complaints.
Arthritis and arthralgia are the commonest rheumatologic
ﬁndings in BD. However, rare musculoskeletal ﬁndings
including osteonecrosis, myalgia, and ﬁbromyalgia may also
be associated with BD [20–22]. Findings relevant to bone
metabolism is lacking. Studies regarding the prevalence and
characteristics of musculoskeletal ﬁndings in patients with
BD are still to be investigated.
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